Frexalimab for Multiple Sclerosis Explained by Neurologist

Sanofi is developing Frexalimab to treat relapsing and progressive multiple sclerosis. It targets CD40L which stimulates the proliferation of t-cells. However effective is it, and is there a risk of infection and clotting? This video reviews the result of a recent phase II trial.